Naloxone hydrochloride (DrugBank: Naloxone)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 226 | 間質性膀胱炎（ハンナ型） | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-018118-21-CZ (EUCTR) | 09/08/2010 | 10/06/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Hungary;Czech Republic;Germany;United Kingdom | |||
| 2 | EUCTR2009-018118-21-HU (EUCTR) | 04/08/2010 | 21/05/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Czech Republic;Hungary;Germany;United Kingdom | |||
| 3 | EUCTR2009-018118-21-DE (EUCTR) | 10/05/2010 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Other descriptive name: OXYCODONE HYDROCHLORIDE Other descriptive name: NALOXONE HYDROCHLORIDE Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release t | Mundipharma Research GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: no | 70 | Czech Republic;Hungary;Germany;United Kingdom |